Have a personal or library account? Click to login
Rare cancers are common: time to act Cover

Rare cancers are common: time to act

Forum of Clinical Oncology
Volume 11 (2020): Issue 3 (December 2020)
By: Michalis Liontos,  Evangelos Karamitrousis,  Nikolaos Tsoukalas and  Ioannis Boukovinas  
Open Access
|Apr 2021

References

  1. Casali P.G. and A. Trama, Rationale of the rare cancer list: a consensus paper from the Joint Action on Rare Cancers (JARC) of the European Union (EU). ESMO open, 2020. 5(2): e000666.
    Search in Google ScholarBack to article
  2. EU. [cited 2020 26/11/2020]; Available from: rarecacner.eu.
    Search in Google ScholarBack to article
  3. Gatta G., et al., Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study. The Lancet Oncology, 2017. 18(8): 1022-1039.
    Search in Google ScholarBack to article
  4. Pourtsidis A., et al. Acinar cell carcinoma in childhood: A case report of a very rare tumor. Forum Clin Oncol. 2020; 11(2):3-8.
    Search in Google ScholarBack to article
  5. Mohammad A, et al. Targeted therapy in advanced desmoid tumors: Current Perspectives. Forum Clin Oncol. 2020; 11(2):9-16.
    Search in Google ScholarBack to article
DOI: https://doi.org/10.2478/fco-2019-0024 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Journal RSS Feed
Language: English
Page range: 1 - 2
Published on: Apr 22, 2021
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology

© 2021 Michalis Liontos, Evangelos Karamitrousis, Nikolaos Tsoukalas, Ioannis Boukovinas, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 11 (2020): Issue 3 (December 2020)Next article